Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open-label, Single-arm, Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Trial Profile

A Phase I/II Open-label, Single-arm, Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Ruxolitinib (Primary) ; Calcineurin inhibitors; Corticosteroids
  • Indications Graft-versus-host disease
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 13 Jan 2019 Planned initiation date (Estimated date of first participant enrollement) changed from 31 Jan 2019 to 30 Apr 2019.
    • 30 Nov 2018 Planned initiation date (Estimated date of first participant enrollement) changed to 31 Jan 2019.
    • 10 Oct 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top